IoM Drug Safety Review Should Reach Beyond FDA, Agency’s Woodcock Says
Executive Summary
The scope of the Institute of Medicine's assessment of the U.S. drug safety system must extend beyond an evaluation of FDA's capabilities, FDA Acting Deputy Commissioner for Operations Janet Woodcock said June 8
You may also be interested in...
Pharma Spends 0.3% Of Sales On Post-Market Safety Activities, CERT Says
Pharmaceutical companies spend an average 0.3% of sales on post-marketing safety studies, an unpublished Centers for Education & Research on Therapeutics report finds
Pharma Spends 0.3% Of Sales On Post-Market Safety Activities, CERT Says
Pharmaceutical companies spend an average 0.3% of sales on post-marketing safety studies, an unpublished Centers for Education & Research on Therapeutics report finds
WLF Questions Ad Division Allegations; “DDMAC Watch” Starts With Strattera
Direct-to-consumer advertising does not endanger the public health because access to prescription drugs is controlled by physicians, not the public, the Washington Legal Foundation's new advertising regulation watchdog group suggests